Understanding how adenovirus vectors can be better used to treat cancer
Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla
This study is looking at how well a special virus can help fight cancer by killing tumor cells and boosting the immune system, using mice to see how different amounts of the virus can improve survival and immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11074616 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of adenovirus-based vectors in treating cancer, particularly focusing on their ability to kill tumor cells and stimulate the immune response. The study uses mouse models to explore how different doses of the virus affect survival rates and immune cell activation. By examining the mechanisms behind the varying responses to treatment, the research aims to identify factors that limit the effectiveness of these vectors in real-world scenarios.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer that may benefit from adenovirus-based treatments.
Not a fit: Patients with cancers that are not responsive to adenovirus therapies or those who have contraindications for viral treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer therapies that utilize adenovirus vectors more effectively, potentially enhancing patient outcomes.
How similar studies have performed: Previous research has shown promise in using adenovirus vectors for cancer treatment, but this specific approach to understanding their limitations is novel.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Shayakhmetov, Dmitry — Emory University
- Study coordinator: Shayakhmetov, Dmitry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.